Mark O'Connor is the Chief Scientist at AstraZeneca, specializing in Oncology R&D. Since joining AstraZeneca in 2010, O'Connor has played a key role as Senior Principal Scientist, leading the DNA Damage Response (DDR) biology area and overseeing a portfolio that includes multiple clinical trials. Before this position, O'Connor was the Chief Scientist at KuDOS Pharmaceuticals, where they directed the DDR discovery strategy and contributed to the development of the first targeted PARP inhibitor. O'Connor holds a BSc (Hons) in Microbiology and a PhD in Molecular Genetics from the University of Bristol.
This person is not in the org chart
This person is not in any teams
This person is not in any offices